Classement en actions
#35026
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the... Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidney disease by specifically targeting and eliminating excess acid within the gastrointestinal tract. The company was established in 2013 and is headquartered in South San Francisco, California.
Prix de l'action
$0.108
Dernière synchronisation: 2023-01-23
Capitalisation boursière
$4.56M
Changement (1 jour)
-10.00%
Échange Tricida, Inc. (TCDA)
Le prix TCDA avec la capitalisation boursière de B
Capitalisation boursière de Tricida, Inc.(TCDA)
Capitalisation boursière: $4.56M
En August 2026, Tricida, Inc. a une capitalisation boursière de $4.56M. Cela fait de Tricida, Inc. la 35026th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Tricida, Inc. du 2018 au 2026
TCDA par rapport au top 5 des plus populaires stocks
| Prix pour TCDA |
|
L’actif B |
La capitalisation boursière de B |
Résultats |
|
|
|
|
$5.452T
|
+119,424,252.46%
|
|
|
|
|
$4.490T
|
+98,354,771.67%
|
|
|
|
|
$4.162T
|
+91,178,334.11%
|
|
|
|
|
$3.676T
|
+80,530,983.42%
|
|
|
|
|
$2.833T
|
+62,058,316.97%
|
